FDA Inspection
The Procter & Gamble Manufacturing CompanyThe Procter & Gamble Manufacturing Company – FDA Inspection, Jun 9, 2026
Record Details
This FDA Inspection record concerns The Procter & Gamble Manufacturing Company, with an inspection on June 9, 2026, issued by the Atlanta District Office, covering human drugs.
View Company Profile
ID · 6f5ce3be-5e9d-4013-9ec7-ed94a5bd0e03
Inspection Facts
- Inspection number
- 1311376
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
4- 21 CFR 211.115(a)Reprocessing procedures lack steps to be taken
- 21 CFR 211.166(a)Written program not followed
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.194(a)(1)Description and Identification of Samples
Full citation text and observation details available on the Dashboard.
Other FDA inspections of The Procter & Gamble Manufacturing Company
6| Date | Classification | Office | Project area |
|---|---|---|---|
| March 10, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| November 17, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 6, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 18, 2013 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 5, 2010 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for The Procter & Gamble Manufacturing Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.